<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408418</article-id><article-id pub-id-type="pmc">PMC12101711</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0323822</article-id><article-id pub-id-type="publisher-id">PONE-D-25-15043</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Science</subject><subj-group><subject>Cognitive Psychology</subject><subj-group><subject>Perception</subject><subj-group><subject>Sensory Perception</subject><subj-group><subject>Vision</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Cognitive Psychology</subject><subj-group><subject>Perception</subject><subj-group><subject>Sensory Perception</subject><subj-group><subject>Vision</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Cognitive Psychology</subject><subj-group><subject>Perception</subject><subj-group><subject>Sensory Perception</subject><subj-group><subject>Vision</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Sensory Perception</subject><subj-group><subject>Vision</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Eye Diseases</subject><subj-group><subject>Retinal Disorders</subject><subj-group><subject>Retinal Detachment</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Ophthalmology</subject><subj-group><subject>Eye Diseases</subject><subj-group><subject>Retinal Disorders</subject><subj-group><subject>Retinal Detachment</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Ophthalmic Procedures</subject><subj-group><subject>Vitrectomy</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Necrosis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Asia</subject><subj-group><subject>Japan</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Science</subject><subj-group><subject>Cognitive Psychology</subject><subj-group><subject>Perception</subject><subj-group><subject>Sensory Perception</subject><subj-group><subject>Vision</subject><subj-group><subject>Visual Acuity</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Cognitive Psychology</subject><subj-group><subject>Perception</subject><subj-group><subject>Sensory Perception</subject><subj-group><subject>Vision</subject><subj-group><subject>Visual Acuity</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Cognitive Psychology</subject><subj-group><subject>Perception</subject><subj-group><subject>Sensory Perception</subject><subj-group><subject>Vision</subject><subj-group><subject>Visual Acuity</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Sensory Perception</subject><subj-group><subject>Vision</subject><subj-group><subject>Visual Acuity</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Protocol for Japan&#x02013;acute retinal necrosis (J-ARN) registry: A combined prospective and retrospective cohort study</article-title><alt-title alt-title-type="running-head">Japan&#x02013;acute retinal necrosis (J-ARN) registry</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1258-3587</contrib-id><name><surname>Usui</surname><given-names>Yoshihiko</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Kinouchi</surname><given-names>Reiko</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nakano</surname><given-names>Satoko</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Iwahashi</surname><given-names>Chiharu</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hase</surname><given-names>Keitaro</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nagata</surname><given-names>Kenji</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sugimoto</surname><given-names>Masahiro</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="aff007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hasegawa</surname><given-names>Eiichi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tsubota</surname><given-names>Kinya</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kusuhara</surname><given-names>Sentaro</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><xref rid="aff009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Akiyama</surname><given-names>Masato</given-names></name><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kashiwagi</surname><given-names>Kenji</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Takeda</surname><given-names>Atsunobu</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kaburaki</surname><given-names>Toshikatsu</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Goto</surname><given-names>Hiroshi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sonoda</surname><given-names>Koh-Hei</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="aff008" ref-type="aff">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Ophthalmology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Ophthalmology, Oita University, Yufu, Japan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Ophthalmology, Kindai University Faculty of Medicine, Osaka, Japan</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Institute of Medical Science, Tokyo Medical University, Tokyo, Japan</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Division of Ophthalmology, Graduate School of Medical Sciences, Kobe University, Kobe, Japan</addr-line></aff><aff id="aff010"><label>10</label>
<addr-line>Department of Ophthalmology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan</addr-line></aff><aff id="aff011"><label>11</label>
<addr-line>Department of Ophthalmology, Jichi Medical University, Shimotsuke-City, Tochigi, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Tucker</surname><given-names>Jennifer</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>PLOS: Public Library of Science, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>usuyoshi@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0323822</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Usui et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Usui et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0323822.pdf">
</self-uri><abstract><sec id="sec012"><title>Background</title><p>Acute retinal necrosis (ARN) is a rare but vision-threatening viral retinitis that can lead to severe visual impairment or blindness if not diagnosed and treated promptly. However, due to its rarity, there are limited large-scale data on the clinical characteristics, treatment approaches, and outcomes of ARN in Japan. A nationwide registry is needed to systematically collect data on ARN cases across Japan to improve understanding of this condition and optimize patient care. We have designed a national registry that collects data of patient characteristics, diagnosis, treatment, and visual outcome to generate evidence for the management of ARN.</p></sec><sec id="sec013"><title>Methods and design</title><p>This research is a combined retrospective and prospective, multicenter cohort study of ARN in Japan from 1 April 2014&#x02013;31 March 2029 (UMIN000056246). The registry has received Japan-wide approval from a national human research ethics committee. The following data will be collected: patient demographics, visual function at the initial visit and 6, 12, 24, and 36 months later, image data, diagnostic methods, virus analysis, indications and timing of vitrectomy, and complications. Customized software and platforms have been designed to permit data collection for a single baseline and multiple follow-up forms.</p></sec><sec id="sec014"><title>Discussion</title><p>By analyzing the accumulated patient information, the results of this study will generate real-world evidence that will contribute to solve various important clinical issues in ARN. The results will be presented after data collection and analysis are completed.</p></sec></abstract><funding-group><award-group id="award001"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap>
</funding-source><award-id>JP24ek0109738h</award-id><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1258-3587</contrib-id>
<name><surname>Usui</surname><given-names>Yoshihiko</given-names></name>
</principal-award-recipient></award-group><funding-statement>This study is supported by AMED Grant Number JP24ek0109738h, received by YU, RK, SN, CI, KH, KN, EH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data from this study will be made available upon study completion.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data from this study will be made available upon study completion.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>I<sc>ntroduction</sc></title><p>Acute retinal necrosis (ARN) is a rare but severe infectious uveitis syndrome characterized by rapid necrosis of the retina, occlusive vasculopathy, and intense inflammatory responses within the eye. Delay in diagnosis and treatment can result in vision loss. This condition was first described in Japan in 1971 by Urayama et al. [<xref rid="pone.0323822.ref001" ref-type="bibr">1</xref>], and has since been recognized worldwide as a potentially sight-threatening ocular emergency. The causative agents of ARN are primarily members of the Herpesviridae family, including herpes simplex virus (HSV) types 1 and 2, and varicella-zoster virus (VZV). In Japan, real-time polymerase chain reaction (PCR) analysis of intraocular fluids is not covered by the universal health insurance system (public health insurance). However, identification of viral agents by performing PCR on intraocular fluid samples facilitates a definitive diagnosis of ARN [<xref rid="pone.0323822.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pone.0323822.ref004" ref-type="bibr">4</xref>]. Nevertheless, the diagnosis of ARN is primarily clinical, based on characteristic fundoscopic findings and supported by real-time PCR. A distinct feature of ARN is peripheral necrotic lesions that circumferentially progress to the posterior pole accompanied by occlusive vasculopathy, which is one of the diagnostic criteria of ARN [<xref rid="pone.0323822.ref002" ref-type="bibr">2</xref>]. The management of ARN poses several challenges, including difficulties in early diagnosis, variable responses to treatment, and a high rate of complications. The rapid progression of retinal necrosis and the potential of bilateral involvement necessitate prompt and aggressive intervention. However, the rarity of the condition and the lack of standardized treatment protocols complicate management. Moreover, the long-term prognosis remains guarded, with many patients experiencing recurrent episodes and permanent vision loss.</p><p>ARN is a relatively rare condition, with an annual incidence estimated at 0.63 cases per million population in the United Kingdom [<xref rid="pone.0323822.ref005" ref-type="bibr">5</xref>]. In Japan, ARN accounts for approximately 1.7% of all uveitis cases, underscoring its rarity but significant impact on those affected [<xref rid="pone.0323822.ref006" ref-type="bibr">6</xref>]. In Japan, where ARN has been recognized and studied extensively, the establishment of a nationwide registry represents a significant step toward improving patient care and advancing research in this challenging field. By consolidating data from multiple institutions, the registry will enable large-scale analyses that are not feasible in individual case reports or small case series. A report on the association between initial treatment regimen and retinal detachment rate and visual outcomes in patients with ARN in the American Academy of Ophthalmology IRIS<sup>&#x000ae;</sup> Registry (Intelligent Research in Sight) has been published [<xref rid="pone.0323822.ref007" ref-type="bibr">7</xref>]. The insights gained from the nationwide registry in Japan will also be instrumental in addressing critical clinical questions, standardizing diagnostic and treatment protocols, and ultimately enhancing the quality of care for patients with ARN.</p><p>The primary objectives of the registry are to (1) characterize the clinical features, diagnostic approaches, virus type, and treatment patterns of ARN; (2) assess visual and anatomic outcomes in ARN patients treated with or without surgery; (3) identify visual prognostic factors associated with outcomes; and (4) compare the effectiveness of different treatment regimens. This information would provide valuable insights into ARN epidemiology, clinical features, treatment responses, and long-term outcomes. Such data are essential for developing evidence-based guidelines and optimizing management strategies. The registry would also facilitate collaborative research efforts facilitating the identification of prognostic factors and the evaluation of novel therapeutic approaches.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Study design and ethical considerations</title><p>The nationwide registry is named &#x0201c;Japan-acute retinal necrosis (J-ARN) registry&#x0201d;. The present research is a combined prospective and retrospective, multicenter, observational study of ARN in Japan from 1 April 2014&#x02013;31 March 2029. The use of a combined retrospective and prospective design is due to the limited scope of the research that focuses on a rare and intractable disease with diverse treatment approaches. Recruiting a large number of participants is anticipated to be challenging.</p><p>During the prospective recruitment phase, participating sites will enroll consecutive patients as they visit for routine follow-up, to reduce the risk of selection bias, and <xref rid="pone.0323822.g001" ref-type="fig">Fig 1</xref> outlines timepoints of enrolment, interventions, and outcomes. Recruitment commenced on 1 April 2025. For the retrospective component, medical records of the prospectively recruited patients will be reviewed retrospectively back to 1 April 2014, to accurately determine the index date of the initial diagnosis of ARN. This hybrid approach aims to maximize the use of available data while ensuring robust and unbiased participant inclusion, despite the challenges associated with studying a rare disease.</p><fig position="float" id="pone.0323822.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0323822.g001</object-id><label>Fig 1</label><caption><title>SPIRIT flow diagram for the schedule of enrolement, interventions, and assessments in our prospective study.</title><p>Abbreviations: visual acuity (VA), herpes simplex virus (HSV), varicella zoster virus (VZV), proliferative vitreoretinopathy (PVR).</p></caption><graphic xlink:href="pone.0323822.g001" position="float"/></fig><p>The Oita University Hospital Clinical Research Supervision Center, Biomedical Research Ethics Review Board approved the study protocol (No. 2810-D28) on 23 May 2024, and the study is registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000056246). The Tokyo Medical University Hospital Research Ethics Committee approved the study protocol (No. E2024-0071) on 1 November 2024. The study will adhere to the principles of the Declaration of Helsinki and the Ethical Guidelines for Life Science and Medical Research Involving Human Patients.</p><p>For the prospective component of the study, written informed consent will be obtained from all recruited participants, including consent for the PCR assay. However, written informed consent from patients will not be required for retrospective review of clinical charts, as the study design does not involve randomization. Instead, an opt-out approach will be employed in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects.</p></sec><sec id="sec004"><title>Sample size, inclusion and exclusion criteria</title><p>The goal of the study is to register a total of 500 eyes treated for ARN. The sample size was determined based on an estimation of number of eligible patients from a national uveitis survey in Japan [<xref rid="pone.0323822.ref006" ref-type="bibr">6</xref>]. Patients who meet the international diagnostic criteria for ARN and who have given written consent to participate in the prospective study, including intraocular fluid examination, will be eligible for registration [<xref rid="pone.0323822.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0323822.ref008" ref-type="bibr">8</xref>]. Exclusion criteria are: (1) patient with retinal necrosis caused by pathogens other than HSV-1, HSV-2 or VZV, such as cytomegalovirus (CMV), (2) patient deemed unsuitable for the study by the investigator, and (3) patient in whom related diseases cannot be excluded despite meeting the inclusion criteria. In the case of exclusion from the study, clinical data until the date of consent acquisition will be registered, after which the study will be terminated.</p></sec><sec id="sec005"><title>Diagnosis</title><p>Acute retinal necrosis is diagnosed based on the standard diagnostic criteria [<xref rid="pone.0323822.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0323822.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0323822.ref009" ref-type="bibr">9</xref>], including typical clinical presentation with peripheral necrotizing retinitis, and positive virologic tests using PCR analysis of intraocular fluids.</p></sec><sec id="sec006"><title>Registered data</title><p>The following data will be collected (<xref rid="pone.0323822.t001" ref-type="table">Table 1</xref>): height, weight, age, sex, laterality of ARN, medication history, history of shingles vaccination and herpetic diseases, drinking and smoking history, systemic disease, ocular disease, days from onset of ocular symptoms to first visit, subjective symptoms, best-corrected visual acuity, spherical equivalent, intraocular pressure, axial length, lens status, slit lamp finding (anterior chamber cells and flares, mutton-fat keratic precipitates), presence of vitreous opacity, fundus appearance (extent of yellowish white lesions), presence of retinal holes/tears, status of optic disc (swelling, redness, atrophy), status of the macula (edema, epiretinal membrane, necrosis), optical coherence tomography (OCT) data, treatment (antiviral agents, systemic corticosteroid, photocoagulation), date of surgery, surgical procedure, and complication.</p><table-wrap position="float" id="pone.0323822.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0323822.t001</object-id><label>Table 1</label><caption><title>List of information collected for J-ARN registry.</title></caption><alternatives><graphic xlink:href="pone.0323822.t001" id="pone.0323822.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Clinical data at initial visit</th><th align="left" rowspan="1" colspan="1">Treatment method, timing and adverse events</th><th align="left" rowspan="1" colspan="1">Events and viral copy number</th><th align="left" rowspan="1" colspan="1">Findings at 6, 12, 24, 36 months after initial visit</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Height</td><td align="left" rowspan="1" colspan="1">Antiviral agents (intravitreal and/or intravenous and/or oral)</td><td align="left" rowspan="1" colspan="1">Maximum extension of yellow-white lesions</td><td align="left" rowspan="1" colspan="1">Best-corrected visual acuity</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight</td><td align="left" rowspan="1" colspan="1">Systemic corticosteroids</td><td align="left" rowspan="1" colspan="1">Period until progression of yellow-white lesion stops</td><td align="left" rowspan="1" colspan="1">Slit lamp findings (AC cells, flare, mutton-fat KPs)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Photocoagulation</td><td align="left" rowspan="1" colspan="1">Development of retinal detachment</td><td align="left" rowspan="1" colspan="1">Presence of retinal detachment</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">Surgery</td><td align="left" rowspan="1" colspan="1">Development of proliferative vitreoretinopathy</td><td align="left" rowspan="1" colspan="1">Presence of optic nerve atrophy</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="left" rowspan="1" colspan="1">Number of vitrectomy</td><td align="left" rowspan="1" colspan="1">Recurrence of ARN</td><td align="left" rowspan="1" colspan="1">Status of the macula (edema, epiretinal membrane, necrosis)</td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic disease</td><td align="left" rowspan="1" colspan="1">Intraocular tamponade materials</td><td align="left" rowspan="1" colspan="1">Development of ARN in the contralateral eye</td><td align="left" rowspan="1" colspan="1">Presence of proliferative vitreoretinopathy</td></tr><tr><td align="left" rowspan="1" colspan="1">History of herpetic disease</td><td align="left" rowspan="1" colspan="1">Intraoperative and postoperative complications</td><td align="left" rowspan="1" colspan="1">Viral copy number measured during follow-up period</td><td align="left" rowspan="1" colspan="1">Presence of silicone oil</td></tr><tr><td align="left" rowspan="1" colspan="1">History of ocular disease</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Complications</td></tr><tr><td align="left" rowspan="1" colspan="1">History of shingles vaccine</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Medication history</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoking history</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Days from onset of ocular symptoms to first visit</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lesion laterality</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Subjective symptoms</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Best-corrected visual acuity</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Spherical equivalent</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Intraocular pressure</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Axial length</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lens status</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Slit lamp findings (AC cells, flare, mutton-fat KPs)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Presence of vitreous opacity</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Extent of yellow-white lesions</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Presence of retinal holes/tears</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Status of optic disc (swelling, redness, atrophy)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Status of the macula (edema, epiretinal membrane, necrosis)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Viral copy number of HSV-1, HSV-2 or VZV</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Abbreviations: AC, anterior chamber; ARN; acute retinal necrosis; KP, keratic precipitates; HSV, herpes simplex virus; VZV, varicella zoster virus</p></fn></table-wrap-foot></table-wrap><p>Decimal best-corrected visual acuity will be evaluated at the initial visit and at follow-up after 6, 12, 24, and 36 months. Decimal best-corrected visual acuity will be converted to logMAR units for statistical analysis. The collected data will be anonymized and registered online. The data center will be located within the hosting service of G-INGS Inc. (Fukuoka, Japan), ensuring maximum security for data storage and management. All data will be reviewed at least twice by the committee. The Committee will contact the participating institution for verification if any inconsistency or outlier is identified. If confirmation is not possible, the Committee will make the final decision.</p><p>A peripheral blood will be collected at the initial visit and thereafter as needed. Nonspecific inflammation tests such as erythrocyte sedimentation rate and blood count are sometimes included in the routine laboratory evaluation. The results of these tests are also essential for initiating therapy with anti-viral drugs and systemic corticosteroids.</p></sec><sec id="sec007"><title>Safety</title><p>Because this is an observational study, participation does not involve any risk beyond those associated with the standard care for ARN in Japan. The registry does not contain any information that could identify patients. Each patient is assigned a unique number, and ophthalmologists are responsible for maintaining separate records of patient identities.</p></sec><sec id="sec008"><title>Publication plan</title><p>The research findings derived from the registry will primarily be disseminated through peer-reviewed publications. These publications are anticipated to guide clinical practice and support the development of educational materials tailored for patients. Furthermore, the results may be shared at international uveitis conferences, aiming to foster global collaboration and knowledge exchange. Authorship of these publications will be attributed to the research group, which will include participating ophthalmologists and other research staff.</p></sec><sec id="sec009"><title>Statistical analysis</title><p>The clinical profile as well as medical and surgical treatment options will be analyzed using descriptive statistics. Biostatisticians and information technology experts (M.A and M.S) will be involved in the planning, execution, and evaluation of the analyses. Multivariate analysis will be performed on changes in visual function over time and complications to identify influencing factors. Best-corrected visual acuity (BCVA) is converted to logarithm of the minimum angle of resolution (logMAR), and visual acuity worse than 0.01 is converted according to previous report [<xref rid="pone.0323822.ref010" ref-type="bibr">10</xref>] as follows: counting fingers, 2.6 logMAR; hand motions, 2.9 logMAR; light perception, 3.1 logMAR; no light perception, 3.4 logMAR. Data of continuous variables are expressed as mean and standard deviation or median and range, depending on normality of data distribution. Non-parametric data will be analyzed by Mann-Whitney U test or Kruskal-Wallis test, while parametric data will be analyzed by Student&#x02019;s t-test or one-way ANOVA. Categorical variables will be expressed as total number and percentage, and the data will be analyzed by chi-squared test or Fisher&#x02019;s exact test. The impact of clinical presentations, viral load, diagnostic methods, treatments, and complications will be estimated by odds ratios (ORs) with 95% confidence intervals (CIs). Survival analyses, especially Kaplan-Meier estimates, will be performed to evaluate visual prognosis, progression-free interval, and complications. Time-to-event data for 6, 12, 24, 36 month from the initial visit, the date of diagnosis, and/or vitrectomy were analyzed. A P value less than 0.05 will be considered statistically significant. Multivariate analyses (such as logistic regression analysis, cox proportional hazards regression, generalized estimating equations, and covariance structure analysis) will consider potential confounding variables related to treatment selection and outcomes.</p><p>There are primarily four types of machine learning algorithms: random forests, support vector machines, decision trees, and simple Bayesian classifiers. These algorithms are employed to integrate clinical data and image information for analysis purposes. Support vector machines utilize distinct kernels, and each method option and parameter is selected through cross-validation and bootstrap methods. This process aims to identify the combination that optimizes generalization. In contrast to deep learning, which necessitates a substantial number of cases, these machine learning methods ensure a certain level of accuracy even with a limited number of cases. The machine learning algorithms are designed to predict the outcomes of disease onset, diagnosis, treatment, visual function, and clinical decision-making.</p></sec><sec sec-type="conclusions" id="sec010"><title>Discussion</title><p>Acute retinal necrosis (ARN) is a severe, rapidly progressive viral uveitis that leads to significant visual impairment or blindness if not treated promptly [<xref rid="pone.0323822.ref011" ref-type="bibr">11</xref>]. Despite advances in antiviral therapies and minimally invasive surgery, ARN remains a challenging disease to manage due to its aggressive nature and the complexity of its diagnosis and treatment. This article reports on the development of Japan&#x02019;s national clinical registry, which will provide real-world data on the clinical course, management, and visual outcome of ARN. Using a multicenter approach, we aim to overcome the challenge posed by the low prevalence of ARN, which has been a major obstacle to advancing research and improving suboptimal outcomes. In addition to tracking visual outcomes associated with different treatment modalities, the registry will serve as a valuable resource for addressing key controversies surrounding the management of ARN. The mainstay for ARN treatment is systemic antiviral therapy, although which specific antiviral agent (e.g., acyclovir, ganciclovir or foscarnet) is superior to the others remains to be identified. In addition to systemic antiviral therapy, numerous studies have evaluated the therapeutic effects of adjunctive treatments such as intravitreal antiviral injections, systemic steroids, systemic immunosuppressants, prophylactic laser therapy, and prophylactic vitrectomy for the management of ARN and the prevention of retinal detachment [<xref rid="pone.0323822.ref012" ref-type="bibr">12</xref>&#x02013;<xref rid="pone.0323822.ref015" ref-type="bibr">15</xref>]. The role of early and/or prophylactic vitrectomy in eyes without retinal detachment has been the subject of considerable debate. Some studies, such as that of Ishida et al. [<xref rid="pone.0323822.ref016" ref-type="bibr">16</xref>], have reported that prophylactic vitrectomy may be effective in preventing retinal detachment. However, other studies from Japan have shown that prophylactic vitrectomy does not improve visual outcome, because the outcome is largely determined by the extent of retinal and optic nerve damage at presentation, irrespective of the presence or absence of retinal detachment [<xref rid="pone.0323822.ref017" ref-type="bibr">17</xref>]. According to a meta-analysis of 265 eyes with ARN conducted by Fan et al. [<xref rid="pone.0323822.ref018" ref-type="bibr">18</xref>], prophylactic vitrectomy reduces the risk of retinal detachment. These findings suggest that although prophylactic vitrectomy may be beneficial in certain cases, it may not universally prevent retinal detachment in ARN patients due to the variability in efficacy. Therefore, the decision to perform prophylactic vitrectomy should be individualized, taking into account the extent of necrotic lesions and potential postoperative complications. The registry may provide insight into the effectiveness of different treatment regimens and their impact on visual outcome.</p><p>This registry has the potential to resolve the controversies by documenting patterns of clinical features, standardizing test procedures such as intraocular fluid sampling, and reviewing cases of misdiagnosis. Another important question that remains unanswered is the optimal approach to vitrectomy in patients with ARN&#x02014;whether silicone oil tamponade, gas tamponade, scleral buckling, and photocoagulation should be used. The registry can address this issue by tracking visual outcomes after vitrectomy. The underlying challenge is the lack of robust evidence to determine the most effective treatment strategies for ARN patients, such as the type of treatment, whether to perform a vitrectomy alone or a combined procedure, and the timing of adjustment to the treatment regimen.</p><p>The second rationale for the proposed study is related to the fact that the number of viral copies in the intraocular fluids of patients with ARN significantly affects the visual prognosis of ARN.<sup>19-21</sup> Calvo et al. [<xref rid="pone.0323822.ref019" ref-type="bibr">19</xref>] identified the presence of more than 5.0&#x02009;&#x000d7;&#x02009;10<sup>6</sup> copies of VZV DNA in the aqueous humor of ARN patients as a poor prognostic factor. Another study [<xref rid="pone.0323822.ref020" ref-type="bibr">20</xref>] and our previous study [<xref rid="pone.0323822.ref004" ref-type="bibr">4</xref>] have reported that VZV-ARN is associated with a higher risk of retinal detachment. In general, VZV-ARN may be associated with worse visual prognosis compared to HSV-ARN [<xref rid="pone.0323822.ref020" ref-type="bibr">20</xref>], but a recent meta-analysis found no evidence to support a difference in visual outcome [<xref rid="pone.0323822.ref021" ref-type="bibr">21</xref>]. Therefore, a better understanding of virus types, viral copy number and clinical features may be important to improve visual prognosis of ARN and guide treatment options. In this regard, the proposed study provides an opportunity to expand current understanding of ARN.</p><p>Despite aggressive treatment, ARN carries a poor prognosis with high rates of retinal detachment and severe visual impairment [<xref rid="pone.0323822.ref004" ref-type="bibr">4</xref>]. A recent study reported that initial retinal detachment was detected in 2% of ARN patients, increasing to 47% during the follow-up period [<xref rid="pone.0323822.ref013" ref-type="bibr">13</xref>]. However, even after successful retinal reattachment, visual outcome often remains poor due to complications such as maculopathy and optic neuropathy [<xref rid="pone.0323822.ref022" ref-type="bibr">22</xref>]. The registry will track long-term outcomes including visual acuity, retinal detachment rate, complications, and recurrence, providing valuable data to guide future management strategies. Several studies have reported a significant association between the involved zone and the development of retinal detachment [<xref rid="pone.0323822.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0323822.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0323822.ref026" ref-type="bibr">26</xref>]. Furthermore, patients aged 50 years or younger diagnosed with ARN are more likely to develop retinal detachment and more severe ocular inflammation [<xref rid="pone.0323822.ref027" ref-type="bibr">27</xref>]. Several studies have investigated the prognostic factors that influence the clinical outcome of ARN. Choi et al. [<xref rid="pone.0323822.ref028" ref-type="bibr">28</xref>] identified poor initial visual acuity, necrotic retinitis in the central zone, and delayed retinal detachment onset as factors that significantly increase the risk of severe vision loss. Kim et al. [<xref rid="pone.0323822.ref024" ref-type="bibr">24</xref>] found that early diagnosis correlated strongly with better visual outcomes. Butler et al. [<xref rid="pone.0323822.ref025" ref-type="bibr">25</xref>] reported that zone 1 involvement and widespread retinal lesions were associated with worse visual prognosis. The proposed registry will evaluate the association between the development of retinal detachment and various clinical characteristics, and provide valuable data to guide future management strategies.</p><p>This registry study has several limitations. Because ARN is a rare disease, a combined retrospective and prospective study design is adopted to maximize data collection. For example, data extracted retrospectively from medical records may be incomplete due to the inherent limitations of retrospective data collection or insufficient data sources. Consequently, retrospective data may be more susceptible to selection bias than data collected prospectively. Furthermore, in this observational study, treatment methods are determined according to the clinical judgment of the ophthalmologists, making it impossible to control for variability. The number of patients included in the study will be small, and the results may not be generalizable to all regions of Japan. Clinical registries provide valuable opportunities to collect data in real-world clinical settings; however, there are inherent limitations to this research approach. As highlighted by Tan et al. [<xref rid="pone.0323822.ref029" ref-type="bibr">29</xref>] in their review of clinical registries in ophthalmology, limitations of clinical registries include potential selection bias due to the voluntary nature of participation by ophthalmologists. Additionally, missing information and typographical errors in data entry are noteworthy concerns. In future review of the registry, the scope of treatment descriptions could be broadened to include specifics such as the antiviral drugs used (e.g., acyclovir and foscarnet), dosages, and administration methods. This protocol will ensure that the field continues to explore innovative approaches. Accordingly, we expect the scope of data collected in the registry to expand as the project gains momentum.</p></sec></sec><sec sec-type="conclusions" id="sec011"><title>Conclusions</title><p>This study marks the first nationwide multicenter registry for ARN in Japan, and aims to gather detailed information on these patients. The registry will focus on the clinical characteristics, prevalence, treatment decisions, visual outcomes, and progression of ARN. It will also provide comprehensive insight into the etiology and pathogenesis of the disease. Ultimately, this effort aims to establish accurate visual prognoses for various medical and surgical treatments. The results of this registry will significantly enhance our understanding of the management of ARN. By identifying patients who are most likely to benefit from ARN-specific therapies or vitrectomy, the study can potentially improve treatment strategies and outcomes. In addition, this initiative sets the stage for future research to optimize treatment protocols and explore preventive measures against the progression of ARN.</p></sec></body><back><ack><p>The following institutions participating in the J-ARN Registry Project Committee and their collaborators contribute to this work.</p><p>1. Sapporo City General Hospital: Hirotomo Miyamoto, Miho Shimizu, Junya Mori</p><p>2. Hirosaki University Graduate School of Medicine: Shinji Ueno, Aiko Hara</p><p>3. Akita University Hospital: Takeshi Iwase, Jiro Kogo, Mariko Sato</p><p>4. Faculty of Medicine, Yamagata University: Yutaka Kaneko,</p><p>5. Faculty of Medicine, Tohoku University: Kazuki Hashimoto</p><p>6. University of Tsukuba: Gaku Kiuchi, Yumi Hasegawa</p><p>7. Gunma University Hospital: Hideo Akiyama, Yosuke Arai</p><p>8. Dokkyo Medical University Hospital: Shigenari Suzuki</p><p>9. Tokyo Medical University Ibaraki Medical Center: Hidetaka Noma</p><p>10. Jichi Medical University Hospital: Meri Watanabe, Kaburagi Toshikatsu,</p><p>11. Jichi Medical University Saitama Medical Center: Suguru Nakagawa, Akihiro Kageyama, Katsuaki Tanaka</p><p>12. Saitama Medical University Hospital: Kei Shinoda</p><p>13. Saitama Medical University Saitama Medical Center: Hiroto Obata, Takahiro Koizumi</p><p>14. Saitama Red Cross Hospital: Kimiko Okinaga</p><p>15. Chiba University Graduate School of Medicine: Tomoaki Tatsumi</p><p>16. National Defense Medical College Hospital: Masaru Takeuchi, Tomohito Sato</p><p>17. Nippon University Hospital: Takako Oonishi</p><p>18. Tsukazaki Hospital: Atsuki Fukushima</p><p>19. Juntendo University Hospital: Shintaro Nakao, Tosiaki Hirakata</p><p>20. Juntendo University Urayasu Hospital: Ayumi Ouchi, Nobuyuki Ebihara</p><p>21. Yamanashi University Hospital: Yumi Kotoda</p><p>22. National Center for Global Health and Medicine Hospital: Shigeko Yashiro</p><p>23. Keio University School of Medicine: Isami Hayashi</p><p>24. Kyorin University School of Medicine: Hiroshi Keino, Ayame Annabelle Okada, Shoko Saito, Katsuya Nagahori, Mari Kakuta</p><p>25. Miyata Eye Hospital Tokyo Clinic: Hiroshi Takase</p><p>26. Showa University Hospital East Branch: Junichiro Kizaki</p><p>27. The University of Tokyo Hospital: Rie Tanaka</p><p>28. Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology: Miwako Yoshimoto</p><p>29. Institute of Science Tokyo Hospital: Koju Kamoi</p><p>30. Tokyo Women&#x02019;s Medical University Hospital: Ichiro Maruko, Mitsuko Toyoguchi</p><p>31. Teikyo University School of Medicine: Tatsuya Mimura, Yuji Inoue, Ayano Enomoto, Ayako Karakawa</p><p>32. Toho University Sakura Medical Center: Keisuke Yata, Fumihiko Yagi, Ryuya Hashimoto</p><p>33. Toho University Ohashi Medical Center: Koji Kakisu, Yuichi Hori</p><p>34. Nippon Medical School Tamanagayama Hospital: Junko Hori, Hitoshi Goto</p><p>35. Tokai University Hospital: Yoshihiro Nakagawa</p><p>36. Kitazato University School of Medicine: Ako Ooe</p><p>37. Yokohama City University: Kazuaki Kadonosono, Mayu Oba, Maiko Inoue</p><p>38. Yokohama City University: Nobuhisa Mizuki, Yuki Mizuki</p><p>39. Hamamatsu Medical University Hospital: Kaoruko Torii, Akiko Hikoya, Miwa Komori, Nobutaka Tachibana, Hiroki Kaneko</p><p>40. Niigata University Medical &#x00026; Dental Hospital: Shimon Kurosawa</p><p>41. International University of Health and Welfare Hospital: Tomohiko Usui, Toshiyuki Oshidari, Tomoaki Shiba</p><p>42. University of Toyama: Yuko Nakamura</p><p>43. Shinshu University School of Medicine: Toshinori Murata, Yorishige Matsuda</p><p>44. Gifu University Graduate School of Medicine: Masayuki Inuzuka</p><p>45. Aichi Medical University Hospital: Motohiro Kamei, Tadashi Mizuguchi</p><p>46. Fujita Medical University Hospital: Tadashi Mizuguchi, Daisuke Kato</p><p>47. Nagoya University Graduate School of Medicine: Koji M Nishiguchi, Hiroaki Ushida</p><p>48. Nagoya City University Graduate School of Medical Sciences: Takaki Yuguchi, Yukinori Eda, Atsuki Matsumoto, Tsutomu Yasukawa</p><p>49. Mie University Hospital: Mineo Kondo, Yuzen Kashima</p><p>50. Fukui University Hospital: Masakazu Morioka</p><p>51. Shiga University of Medical Science: Tomohiro Sodegawa</p><p>52. Kyoto University Graduate School of Medicine: Akitaka Tsujikawa, Kenji Ishihara, Yuki Muraoka</p><p>53. Osaka Medical and Pharmaceutical University: Takatoshi Kobayashi</p><p>54. Japan Community Heath care Organization Osaka Hospital: Nobuyuki Ohguro</p><p>55. Osaka Metropolitan University Hospital: Shigeru Honda, Mizuki Tagami, Mami Tomita, Yusuke Haruna, Gen Kinari</p><p>56. Yodogawa Christian Hospital: Akira Tanigawa, Kei Nakai</p><p>57. Osaka University Hospital: Kazuichi Maruyama, Koji Nishida</p><p>58. Osaka City General Hospital: Noriyuki Unoki</p><p>59. Kansai Medical University Hospital: Hisanori Imai, Hidetsugu Mori, Shimpei Oba, Kaoru Sasaki</p><p>60. Hyogo Medical University: Takaaki Sugisawa, Yuki Yamamoto, Fumi Gomi</p><p>61. Nara Medical University Hospital: Taisei Tsujinaka, Tetsuo Ueda, Hiroaki Hirai</p><p>62. Wakayama Medical University Hospital: Shingo Yasuda, Hiroki Iwanishi, Nobuyuki Ishikawa</p><p>63. Kurashiki Central Hospital: Akihiro Nishida</p><p>64. Okayama University Graduate School of Medicine: Yuki Morizane, Yusuke Shiode</p><p>65. Hiroshima University Hospital: Yousuke Harada, Tomona Hiyama, Ikuyo Sada</p><p>66. Tottori University Hospital: Ryu Uotani, Dai Miyazaki</p><p>67. Shimane University Faculty of Medicine: Aika Tsutui</p><p>68. Yamaguchi University Hospital: Shohei Uchi</p><p>69. Tokushima University Hospital: Ryoji Yanai</p><p>70. Kagawa University Faculty of Medicine: Kiyoshi Suzuma, Erina Goda</p><p>71. Kochi Medical School, Kochi University: Ken Fukuda, Kenji Yamashiro</p><p>72. Ehime University Hospital: Yukako Hiramatsu</p><p>73. Miyata Eye Hospital: Yukiko Terada</p><p>74. Fukuoka University Hospital: Tomoko Kawamura</p><p>75. University of Occupational and Environmental Health, Japan: Itsuka Matsushita, Hiroyuki Kondo</p><p>76. Kurume University Hospital: Shigeo Yoshida, Yoshiki Kojima, Mariko Tanaka, Yuka Nishihara</p><p>77. Nagasaki University: Akio Oishi, Yuki Hirata, Marina Yamaguchi</p><p>78. Saga University Hospital: Hiroshi Enaida, Hiroaki Sakai 81. Kanazawa University Hospital: Yuko Takemoto, Tomomi Higashide</p><p>79. Kanazawa Medical University Hospital: Tsuyoshi Mito</p><p>80. Oita University Hospital: Ukiko Umemoto</p><p>81. Faculty of Medicine, University of Miyazaki Hospital: Yasuhiro Ikeda, Akira Hayashida</p><p>82. Kagoshima University Graduate School of Medical and Dental Sciences: Hiroto Terasaki, Aoi Machida</p><p>83. University of Ryukyus Hospital: Ayano Oshiro, Hideki Koizumi</p><p>84. Kobe University Hospital: Wataru Matsumiya, Rei Sotani, Yasuyuki Sotani, Daiki Sakai, Risa Masuda, Yuto Iwaki, Naoki Fukushima</p><p>85. Kumamoto University Hospital: Eri Takahashi</p></ack><ref-list><title>References</title><ref id="pone.0323822.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Urayama</surname><given-names>A</given-names></name>. <article-title>Unilateral acute uveitis with periarteritis and detachment.</article-title>
<source>Jpn J Clin Ophthalmol</source>. <year>1971</year>; <volume>25</volume>: <fpage>607</fpage>&#x02013;<lpage>19</lpage>.</mixed-citation></ref><ref id="pone.0323822.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Takase</surname><given-names>H</given-names></name>, <name><surname>Okada</surname><given-names>AA</given-names></name>, <name><surname>Goto</surname><given-names>H</given-names></name>, <name><surname>Mizuki</surname><given-names>N</given-names></name>, <name><surname>Namba</surname><given-names>K</given-names></name>, <name><surname>Ohguro</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Development and validation of new diagnostic criteria for acute retinal necrosis</article-title>. <source>Jpn J Ophthalmol</source>. <year>2015</year>;<volume>59</volume>(<issue>1</issue>):<fpage>14</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10384-014-0362-0</pub-id>
<pub-id pub-id-type="pmid">25492579</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Takase</surname><given-names>H</given-names></name>, <name><surname>Goto</surname><given-names>H</given-names></name>, <name><surname>Namba</surname><given-names>K</given-names></name>, <name><surname>Mizuki</surname><given-names>N</given-names></name>, <name><surname>Okada</surname><given-names>AA</given-names></name>, <name><surname>Ohguro</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Clinical characteristics, management, and factors associated with poor visual prognosis of acute retinal necrosis</article-title>. <source>Ocul Immunol Inflamm</source>. <year>2022</year>;<volume>30</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/09273948.2020.1789179</pub-id>
<pub-id pub-id-type="pmid">32945715</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Usui</surname><given-names>Y</given-names></name>, <name><surname>Takeuchi</surname><given-names>M</given-names></name>, <name><surname>Goto</surname><given-names>H</given-names></name>, <name><surname>Mori</surname><given-names>H</given-names></name>, <name><surname>Kezuka</surname><given-names>T</given-names></name>, <name><surname>Sakai</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Acute retinal necrosis in Japan</article-title>. <source>Ophthalmology</source>. <year>2008</year>;<volume>115</volume>(<issue>9</issue>):<fpage>1632</fpage>&#x02013;<lpage>3</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2008.03.005</pub-id>
<pub-id pub-id-type="pmid">18762074</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Cochrane</surname><given-names>TF</given-names></name>, <name><surname>Silvestri</surname><given-names>G</given-names></name>, <name><surname>McDowell</surname><given-names>C</given-names></name>, <name><surname>Foot</surname><given-names>B</given-names></name>, <name><surname>McAvoy</surname><given-names>CE</given-names></name>. <article-title>Acute retinal necrosis in the United Kingdom: results of a prospective surveillance study</article-title>. <source>Eye (Lond)</source>. <year>2012</year>;<volume>26</volume>(<issue>3</issue>):<fpage>370</fpage>&#x02013;<lpage>7; quiz 378</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/eye.2011.338</pub-id>
<pub-id pub-id-type="pmid">22281865</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Sonoda</surname><given-names>K-H</given-names></name>, <name><surname>Hasegawa</surname><given-names>E</given-names></name>, <name><surname>Namba</surname><given-names>K</given-names></name>, <name><surname>Okada</surname><given-names>AA</given-names></name>, <name><surname>Ohguro</surname><given-names>N</given-names></name>, <name><surname>Goto</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey</article-title>. <source>Jpn J Ophthalmol</source>. <year>2021</year>;<volume>65</volume>(<issue>2</issue>):<fpage>184</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10384-020-00809-1</pub-id>
<pub-id pub-id-type="pmid">33694024</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Lains</surname><given-names>I</given-names></name>, <name><surname>Ivanov</surname><given-names>A</given-names></name>, <name><surname>Ross</surname><given-names>C</given-names></name>, <name><surname>Hall</surname><given-names>N</given-names></name>, <name><surname>Elze</surname><given-names>T</given-names></name>, <name><surname>Lorch</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Treatment regimen and outcomes in acute retinal necrosis: an IRIS&#x000ae; registry study</article-title>. <source>Ophthalmology</source>. <year>2024</year>;<volume>131</volume>(<issue>12</issue>):<fpage>1468</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2024.07.020</pub-id>
<pub-id pub-id-type="pmid">39033858</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Holland</surname><given-names>GN</given-names></name>. <article-title>Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive Committee of the American Uveitis Society</article-title>. <source>Am J Ophthalmol</source>. <year>1994</year>;<volume>117</volume>(<issue>5</issue>):<fpage>663</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0002-9394(14)70075-3</pub-id>
<pub-id pub-id-type="pmid">8172275</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref009"><label>9</label><mixed-citation publication-type="journal"><collab>Standardization of Uveitis Nomenclature (SUN) Working Group</collab>. <article-title>Classification criteria for acute retinal necrosis syndrome</article-title>. <source>Am J Ophthalmol</source>. <year>2021</year>;<volume>228</volume>:<fpage>237</fpage>&#x02013;<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2021.03.057</pub-id>
<pub-id pub-id-type="pmid">33845012</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Schulze-Bonsel</surname><given-names>K</given-names></name>, <name><surname>Feltgen</surname><given-names>N</given-names></name>, <name><surname>Burau</surname><given-names>H</given-names></name>, <name><surname>Hansen</surname><given-names>L</given-names></name>, <name><surname>Bach</surname><given-names>M</given-names></name>. <article-title>Visual acuities &#x0201c;hand motion&#x0201d; and &#x0201c;counting fingers&#x0201d; can be quantified with the freiburg visual acuity test</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2006</year>;<volume>47</volume>(<issue>3</issue>):<fpage>1236</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1167/iovs.05-0981</pub-id>
<pub-id pub-id-type="pmid">16505064</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Usui</surname><given-names>Y</given-names></name>, <name><surname>Goto</surname><given-names>H</given-names></name>. <article-title>Overview and diagnosis of acute retinal necrosis syndrome</article-title>. <source>Semin Ophthalmol</source>. <year>2008</year>;<volume>23</volume>(<issue>4</issue>):<fpage>275</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/08820530802111325</pub-id>
<pub-id pub-id-type="pmid">18584564</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Hillenkamp</surname><given-names>J</given-names></name>, <name><surname>N&#x000f6;lle</surname><given-names>B</given-names></name>, <name><surname>Bruns</surname><given-names>C</given-names></name>, <name><surname>Rautenberg</surname><given-names>P</given-names></name>, <name><surname>Fickenscher</surname><given-names>H</given-names></name>, <name><surname>Roider</surname><given-names>J</given-names></name>. <article-title>Acute retinal necrosis: clinical features, early vitrectomy, and outcomes</article-title>. <source>Ophthalmology</source>. <year>2009</year>;<volume>116</volume>(<issue>10</issue>):1971-5.e2. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2009.03.029</pub-id>
<pub-id pub-id-type="pmid">19592111</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>X-Y</given-names></name>, <name><surname>Meng</surname><given-names>L-H</given-names></name>, <name><surname>Zhang</surname><given-names>W-F</given-names></name>, <name><surname>Wang</surname><given-names>D-Y</given-names></name>, <name><surname>Chen</surname><given-names>Y-X</given-names></name>. <article-title>Retinal detachment after acute retinal necrosis and the efficacies of different interventions: a systematic review and metaanalysis</article-title>. <source>Retina</source>. <year>2021</year>;<volume>41</volume>(<issue>5</issue>):<fpage>965</fpage>&#x02013;<lpage>78</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/IAE.0000000000002971</pub-id>
<pub-id pub-id-type="pmid">32932382</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>H</given-names></name>. <article-title>Efficiency of laser photocoagulation on the prevention of retinal detachment in acute retinal necrosis: a systematic review and meta-analysis</article-title>. <source>Retina</source>. <year>2022</year>;<volume>42</volume>(<issue>9</issue>):<fpage>1702</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/IAE.0000000000003527</pub-id>
<pub-id pub-id-type="pmid">35576609</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>JR</given-names></name>, <name><surname>Thorne</surname><given-names>JE</given-names></name>, <name><surname>Flaxel</surname><given-names>CJ</given-names></name>, <name><surname>Jain</surname><given-names>N</given-names></name>, <name><surname>Kim</surname><given-names>SJ</given-names></name>, <name><surname>Maguire</surname><given-names>MG</given-names></name>, <etal>et al</etal>. <article-title>Treatment of noninfectious uveitic macular edema with periocular and intraocular corticosteroid therapies: a report by the American Academy of Ophthalmology</article-title>. <source>Ophthalmology</source>. <year>2024</year>;<volume>131</volume>(<issue>9</issue>):<fpage>1107</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2024.02.019</pub-id>
<pub-id pub-id-type="pmid">38647511</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Ishida</surname><given-names>T</given-names></name>, <name><surname>Sugamoto</surname><given-names>Y</given-names></name>, <name><surname>Sugita</surname><given-names>S</given-names></name>, <name><surname>Mochizuki</surname><given-names>M</given-names></name>. <article-title>Prophylactic vitrectomy for acute retinal necrosis</article-title>. <source>Jpn J Ophthalmol</source>. <year>2009</year>;<volume>53</volume>(<issue>5</issue>):<fpage>486</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10384-009-0698-z</pub-id>
<pub-id pub-id-type="pmid">19847603</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Iwahashi-Shima</surname><given-names>C</given-names></name>, <name><surname>Azumi</surname><given-names>A</given-names></name>, <name><surname>Ohguro</surname><given-names>N</given-names></name>, <name><surname>Okada</surname><given-names>AA</given-names></name>, <name><surname>Kaburaki</surname><given-names>T</given-names></name>, <name><surname>Goto</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Acute retinal necrosis: factors associated with anatomic and visual outcomes</article-title>. <source>Jpn J Ophthalmol</source>. <year>2013</year>;<volume>57</volume>(<issue>1</issue>):<fpage>98</fpage>&#x02013;<lpage>103</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10384-012-0211-y</pub-id>
<pub-id pub-id-type="pmid">23117419</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Fan</surname><given-names>S</given-names></name>, <name><surname>Lin</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>. <article-title>Role of prophylactic vitrectomy in acute retinal necrosis in preventing rhegmatogenous retinal detachment: systematic review and meta-analysis</article-title>. <source>Ocul Immunol Inflamm</source>. <year>2022</year>;<volume>30</volume>(<issue>2</issue>):<fpage>515</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/09273948.2020.1800051</pub-id>
<pub-id pub-id-type="pmid">32966153</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Calvo</surname><given-names>CM</given-names></name>, <name><surname>Khan</surname><given-names>MA</given-names></name>, <name><surname>Mehta</surname><given-names>S</given-names></name>, <name><surname>Garg</surname><given-names>SJ</given-names></name>, <name><surname>Dunn</surname><given-names>JP</given-names></name>. <article-title>Correlation of clinical outcomes with quantitative polymerase chain reaction DNA copy number in patients with acute retinal necrosis</article-title>. <source>Ocul Immunol Inflamm</source>. <year>2017</year>;<volume>25</volume>(<issue>2</issue>):<fpage>246</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3109/09273948.2015.1115081</pub-id>
<pub-id pub-id-type="pmid">26828388</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>R</given-names></name>, <name><surname>Pavesio</surname><given-names>CE</given-names></name>, <name><surname>Laidlaw</surname><given-names>DAH</given-names></name>, <name><surname>Williamson</surname><given-names>TH</given-names></name>, <name><surname>Graham</surname><given-names>EM</given-names></name>, <name><surname>Stanford</surname><given-names>MR</given-names></name>. <article-title>Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome</article-title>. <source>Ophthalmology</source>. <year>2010</year>;<volume>117</volume>(<issue>3</issue>):<fpage>556</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2009.08.003</pub-id>
<pub-id pub-id-type="pmid">20031221</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Putera</surname><given-names>I</given-names></name>, <name><surname>Ridwan</surname><given-names>AS</given-names></name>, <name><surname>Dewi</surname><given-names>M</given-names></name>, <name><surname>Cifuentes-Gonz&#x000e1;lez</surname><given-names>C</given-names></name>, <name><surname>Rojas-Carabali</surname><given-names>W</given-names></name>, <name><surname>Sitompul</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Antiviral treatment for acute retinal necrosis: a systematic review and meta-analysis</article-title>. <source>Surv Ophthalmol</source>. <year>2024</year>;<volume>69</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.survophthal.2023.09.004</pub-id>
<pub-id pub-id-type="pmid">37774799</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Meghpara</surname><given-names>B</given-names></name>, <name><surname>Sulkowski</surname><given-names>G</given-names></name>, <name><surname>Kesen</surname><given-names>MR</given-names></name>, <name><surname>Tessler</surname><given-names>HH</given-names></name>, <name><surname>Goldstein</surname><given-names>DA</given-names></name>. <article-title>Long-term follow-up of acute retinal necrosis</article-title>. <source>Retina</source>. <year>2010</year>;<volume>30</volume>(<issue>5</issue>):<fpage>795</fpage>&#x02013;<lpage>800</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/IAE.0b013e3181c7013c</pub-id>
<pub-id pub-id-type="pmid">20057342</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Lei</surname><given-names>B</given-names></name>, <name><surname>Zhou</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Chang</surname><given-names>Q</given-names></name>, <name><surname>Xu</surname><given-names>G</given-names></name>, <name><surname>Jiang</surname><given-names>R</given-names></name>. <article-title>Ultra-wide-field fundus imaging of acute retinal necrosis: clinical characteristics and visual significance</article-title>. <source>Eye (Lond)</source>. <year>2020</year>;<volume>34</volume>(<issue>5</issue>):<fpage>864</fpage>&#x02013;<lpage>72</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41433-019-0587-8</pub-id>
<pub-id pub-id-type="pmid">31554945</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>DY</given-names></name>, <name><surname>Jo</surname><given-names>J</given-names></name>, <name><surname>Joe</surname><given-names>SG</given-names></name>, <name><surname>Lee</surname><given-names>JY</given-names></name>, <name><surname>Yoon</surname><given-names>YH</given-names></name>, <name><surname>Kim</surname><given-names>J-G</given-names></name>. <article-title>Clinical feature and visual prognosis of acute retinal necrosis according to the initially involved zone and extent: 10-year experience</article-title>. <source>Eur J Ophthalmol</source>. <year>2019</year>;<volume>29</volume>(<issue>2</issue>):<fpage>244</fpage>&#x02013;<lpage>50</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1120672118787438</pub-id>
<pub-id pub-id-type="pmid">29998748</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Butler</surname><given-names>NJ</given-names></name>, <name><surname>Moradi</surname><given-names>A</given-names></name>, <name><surname>Salek</surname><given-names>SS</given-names></name>, <name><surname>Burkholder</surname><given-names>BM</given-names></name>, <name><surname>Leung</surname><given-names>TG</given-names></name>, <name><surname>Dunn</surname><given-names>JP</given-names></name>, <etal>et al</etal>. <article-title>Acute retinal necrosis: presenting characteristics and clinical outcomes in a cohort of polymerase chain reaction-positive patients</article-title>. <source>Am J Ophthalmol</source>. <year>2017</year>;<volume>179</volume>:<fpage>179</fpage>&#x02013;<lpage>89</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajo.2017.05.006</pub-id>
<pub-id pub-id-type="pmid">28501392</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Bavinger</surname><given-names>JC</given-names></name>, <name><surname>Anthony</surname><given-names>CL</given-names></name>, <name><surname>Lindeke-Myers</surname><given-names>AT</given-names></name>, <name><surname>Lynch</surname><given-names>S</given-names></name>, <name><surname>Xu</surname><given-names>LT</given-names></name>, <name><surname>Barnett</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Risk factors for retinal detachment in acute retinal necrosis</article-title>. <source>Ophthalmol Retina</source>. <year>2022</year>;<volume>6</volume>(<issue>6</issue>):<fpage>478</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.oret.2022.01.016</pub-id>
<pub-id pub-id-type="pmid">35114414</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Urzua</surname><given-names>CA</given-names></name>, <name><surname>Knickelbein</surname><given-names>J</given-names></name>, <name><surname>Cuitino</surname><given-names>L</given-names></name>, <name><surname>Moreno</surname><given-names>U</given-names></name>, <name><surname>Anguita</surname><given-names>R</given-names></name>, <name><surname>Velasquez</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Association of retinal detachment with age 50 years or younger at onset in patients with acute retinal necrosis.</article-title>
<source>Graefes Arch Clin Exp Ophthalmol</source>. <year>2021</year>;<volume>259</volume>:<fpage>2905</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00417-021-05166-4</pub-id>
<pub-id pub-id-type="pmid">33846837</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>EY</given-names></name>, <name><surname>Lee</surname><given-names>DH</given-names></name>, <name><surname>Jun</surname><given-names>JW</given-names></name>, <name><surname>Byeon</surname><given-names>SH</given-names></name>, <name><surname>Kim</surname><given-names>SS</given-names></name>, <name><surname>Koh</surname><given-names>HJ</given-names></name>, <etal>et al</etal>. <article-title>Therapeutic prognostic factors associated with retinal detachment and visual outcomes in acute retinal necrosis</article-title>. <source>Clin Exp Ophthalmol</source>. <year>2022</year>;<volume>50</volume>(<issue>1</issue>):<fpage>40</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/ceo.14016</pub-id>
<pub-id pub-id-type="pmid">34585833</pub-id>
</mixed-citation></ref><ref id="pone.0323822.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>JCK</given-names></name>, <name><surname>Ferdi</surname><given-names>AC</given-names></name>, <name><surname>Gillies</surname><given-names>MC</given-names></name>, <name><surname>Watson</surname><given-names>SL</given-names></name>. <article-title>Clinical registries in ophthalmology</article-title>. <source>Ophthalmology</source>. <year>2019</year>;<volume>126</volume>(<issue>5</issue>):<fpage>655</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ophtha.2018.12.030</pub-id>
<pub-id pub-id-type="pmid">30572076</pub-id>
</mixed-citation></ref></ref-list></back><sub-article article-type="author-comment" id="pone.0323822.r001" specific-use="rebutted-decision-letter-unavailable"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0323822.r001</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">24 Mar 2025</named-content>
</p></body></sub-article><sub-article article-type="editor-report" id="pone.0323822.r002" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0323822.r002</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tucker</surname><given-names>Jennifer</given-names></name><role>Staff Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Jennifer Tucker</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Jennifer Tucker</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0323822" id="rel-obj002" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">16 Apr 2025</named-content>
</p><p>Protocol for Japan&#x02012;Acute Retinal Necrosis (J-ARN) Registry: A combined prospective and retrospective cohort study</p><p>PONE-D-25-15043</p><p>Dear Dr. Usui,</p><p>We&#x02019;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#x02019;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#x02019;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#x000ae;</ext-link> &#x000a0;and clicking the &#x02018;Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#x02019;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>Kind regards,</p><p>Jennifer Tucker, PhD</p><p>Staff Editor</p><p>PLOS ONE</p><p>Journal requirements:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1.&#x000a0; Thank you for stating the following financial disclosure:</p><p>&#x0201c;This study is supported by AMED Grant Number JP24ek0109738h.&#x0201d;</p><p>Please state what role the funders took in the study.&#x000a0; If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."</p><p>If this statement is not correct you must amend it as needed.</p><p>Please respond by return e-mail so that we can amend your financial disclosure and competing interests on your behalf.</p><p>Additional Editor Comments (optional):</p><p>We are pleased to accept your study protocol for publication in PLOS One.&#x000a0;</p><p>Reviewers' comments:</p></body></sub-article><sub-article article-type="editor-report" id="pone.0323822.r003" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0323822.r003</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tucker</surname><given-names>Jennifer</given-names></name><role>Staff Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Jennifer Tucker</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Jennifer Tucker</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0323822" id="rel-obj003" related-article-type="reviewed-article"/></front-stub><body><p>PONE-D-25-15043</p><p>PLOS ONE</p><p>Dear Dr. Usui,</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>You will receive further&#x000a0;instructions from the production team, including instructions on how to review your proof when it&#x000a0;is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.</p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>If we can help with anything else, please email us at customercare@plos.org.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access.</p><p>Kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr Jennifer Tucker</p><p>Staff Editor</p><p>PLOS ONE</p></body></sub-article></article>